logo

For the Inventor, By the Inventor

Radnor, PA, United States of America

Karyn O'Neil

This inventor holds 39 USPTO granted patents and 5 published patent applications and 14 EPO patents, primarily in Fibronectin Domain Engineering. Top assignees: Janssen Biotech, Inc., Centocor Ortho Biotech Inc., Centocor, Inc.. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Karyn O'Neil. Retrieved from https://idiyas.com/inventor/karyn-o-neil

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 39 

% Patents Active = 69.2

 

Average Co-Inventor Count = 3.3

ph-index = 8

Forward Citations = 290(Granted Patents)


Location History:

  • Kennett Square, PA (US) (2003 - 2010)
  • Radnor, PA (US) (2010 - 2014)
  • Media, PA (US) (2010 - 2022)
  • Spring House, PA (US) (2013 - 2024)

Company Filing History:

goldMedal24 out of 436 
 
Janssen Biotech, Inc.
 patents
silverMedal6 out of 31 
 
Centocor Ortho Biotech Inc.
 patents
bronzeMedal5 out of 144 
 
Centocor, Inc.
 patents
4. 1 out of 3,745 
 
Bristol-Myers Squibb Compnay
 patents
5. 1 out of 1 
 
Centoco Ortho Biotech Inc.
 patent
6. 2 out of 834,601 
Other
 patents

Years Active: 2003-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Fibronectin Domains
Binding Molecules
Scaffold Compositions
Therapeutic Antibodies
Prostate Specific Antigen
IL4/IL13 Proteins
TNF Alpha Inhibitors
GLP-1R Antibodies
Phage Vectors
Insulin Sensitivity
HIV Mimetic Peptides
Integrin Antagonists
39 patents (USPTO):Explore Patents
1. 12304939 - EGFR and C-met fibronectin type III domain binding molecules (2025-05-20),
2. 12291797 - Fibronectin type III domain based scaffold compositions, methods and uses (2025-05-06),
3. 12054534 - Prostate specific membrane antigen binding fibronectin type iii domains (2024-08-06),
4. 11833190 - Serum albumin-binding fibronectin type III domains (2023-12-05),
5. 11702475 - Cysteine engineered fibronectin type III domain binding molecules (2023-07-18),
6. 11479880 - Fibronectin type III domain based scaffold compositions, methods and uses (2022-10-25),
7. 11072663 - Cysteine engineered fibronectin type III domain binding molecules (2021-07-27),
8. 10954284 - EGFR and c-Met fibronectin type III domain binding molecules (2021-03-23),
9. 10925932 - Serum albumin-binding fibronectin type III domains (2021-02-23),
10. 10844122 - Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof (2020-11-24),
11. 10844111 - Prostate specific membrane antigen binding fibronectin type III domains (2020-11-24),
12. 10662235 - Cysteine engineered fibronectin type III domain binding molecules (2020-05-26),
13. 10654913 - Fibronectin type III domain based scaffold compositions, methods and uses (2020-05-19),
14. 10196446 - Cysteine engineered fibronectin type III domain binding molecules (2019-02-05),
15. 10040842 - Fibronectin type III domain based scaffold compositions, methods and uses (2018-08-07),

Title: The Innovative Contributions of Karyn O'Neil

Introduction

Karyn O'Neil, based in Radnor, Pennsylvania, is a prolific inventor with a remarkable portfolio of 37 patents to her name. Her work has significantly contributed to the fields of therapeutic development and diagnostic methodologies, making her a notable figure in the biotechnology sector.

Latest Patents

Among her latest inventions are the patents for Prostate Specific Membrane Antigen Binding Fibronectin Type III Domains and Serum Albumin-Binding Fibronectin Type III Domains. The first patent focuses on PSMA binding FN3 domains, alongside their conjugates, isolated nucleotides, vectors, host cells, and related manufacturing methods. This innovation holds promise for the generation of therapeutic molecules and offers advancements in the treatment and diagnosis of various diseases and disorders. In addition, her patent for fibronectin type III domains that selectively bind to serum albumin includes related polynucleotides and cells expressing these domains. This work is particularly valuable as it can enhance the half-life of molecules in both diagnostic and therapeutic applications.

Career Highlights

Throughout her career, Karyn has collaborated with leading companies such as Janssen Biotech, Inc. and Centocor Ortho Biotech Inc. Her roles within these organizations have facilitated her research into innovative solutions for medical challenges, underscoring her dedication to advancing healthcare.

Collaborations

In her pursuit of innovation, Karyn has worked alongside esteemed colleagues like Steven Jacobs and Linus Hyun. These collaborations have nurtured a rich environment for knowledge exchange and creativity, further enhancing the impact of her work.

Conclusion

Karyn O'Neil exemplifies dedication and innovation in the biotechnology realm, as reflected in her numerous patents and collaborative efforts. Her pioneering inventions continue to pave the way for advancements in medical diagnostics and therapeutics, establishing her as a significant contributor to the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…